{"schema_version":"secwatch.filing_event.v1","accession":"0001757073-25-000042","form_type":"8-K","ticker":"NVST","cik":"0001757073","company_name":"Envista Holdings Corp","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.890512+00:00","generated_at":"2026-05-17T22:23:58.553297+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15","bullets":["Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).","Core sales growth 5.6% YoY across all businesses and geographies, including Nobel Biocare in North America.","FY2025 guidance raised: core sales growth 3-4% (prior 1-3%), adjusted EPS $1.05-$1.15 (prior $0.95-$1.05).","Repurchased 4.8M shares for ~$82M in Q2; $150M remaining under buyback program.","YTD operating cash flow $89M, free cash flow $71M, down from $133M and $116M in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001757073-25-000042","json":"https://secwatch.observer/filing/0001757073-25-000042.json","markdown":"https://secwatch.observer/filing/0001757073-25-000042.md","text":"https://secwatch.observer/filing/0001757073-25-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000042/0001757073-25-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000042/nvst-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:23:58.553297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}